» Articles » PMID: 2452745

The Glioblastoma-derived T Cell Suppressor Factor/transforming Growth Factor-beta 2 Inhibits T Cell Growth Without Affecting the Interaction of Interleukin 2 with Its Receptor

Overview
Journal Eur J Immunol
Date 1988 Apr 1
PMID 2452745
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Human glioblastoma cells secrete a peptide termed glioblastoma-derived T cell suppressor factor (G-TsF) which inhibits T cell activation. Recently, purification and cloning of G-TsF revealed that G-TsF is identical to transforming growth factor-beta 2. As shown here, G-TsF suppresses the growth of an ovalbumin-specific mouse T helper cell clone (OVA-7T) independently of the stimulus used being either (a) antigen in the presence of antigen-presenting cells, or (b) interleukin 2 (IL2) or (c) phorbol ester and calcium ionophore. Furthermore, in the presence of antibodies against IL2 receptors, G-TsF was able to suppress the residual proliferation still observed when OVA-7T were stimulated with phorbol ester/ionophore. G-TsF failed to inhibit the release of IL3 from OVA-7T activated with IL2. Taken together, the data provide evidence that G-TsF does not directly interfere with interactions of IL2 with its receptor but rather inhibits T cell activation by interfering with an as yet unidentified pathway used by both IL2 and phorbol ester/ionophore. When analyzing different monokines and lymphokines for its effect on G-TsF-induced suppression of T cell growth the only factor found to partially neutralize the effect of G-TsF was tumor necrosis factor-alpha.

Citing Articles

Zonulin as Gatekeeper in Gut-Brain Axis: Dysregulation in Glioblastoma.

Hagemeyer H, Hellwinkel O, Plata-Bello J Biomedicines. 2024; 12(8).

PMID: 39200114 PMC: 11352073. DOI: 10.3390/biomedicines12081649.


Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide.

Otte K, Zhao K, Braun M, Neubauer A, Raifer H, Helmprobst F Biomedicines. 2022; 10(9).

PMID: 36140245 PMC: 9496210. DOI: 10.3390/biomedicines10092145.


Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.

Adhikaree J, Moreno-Vicente J, Kaur A, Jackson A, Patel P Cells. 2020; 9(2).

PMID: 31973059 PMC: 7072315. DOI: 10.3390/cells9020263.


Discovery and initial characterization of Th9 cells: the early years.

Schmitt E, Bopp T Semin Immunopathol. 2016; 39(1):5-10.

PMID: 27896635 DOI: 10.1007/s00281-016-0610-0.


Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Yang L, Guo G, Niu X, Liu J Biomed Res Int. 2015; 2015:717530.

PMID: 26167495 PMC: 4488155. DOI: 10.1155/2015/717530.